Prometic’s intravenous Plasminogen was the first PPPSTM generated plasma derived therapeutic to enter clinical trial stages. In August 2016, the Corporation completed enrolment of the congenital plasminogen deficient patients in its pivotal phase 2/3 clinical trial required for the accelerated regulatory approval pathway with the FDA. In October 2016, it was concluded that the phase 2/3 trial had met its primary and secondary endpoints with the intravenous plasminogen treatment. In addition to being safe, well tolerated and without any drug related serious adverse events, Prometic’s plasminogen treatment achieved a 100% success rate of its primary end point, namely, a targeted increase in the blood plasma concentration level of plasminogen as a surrogate target. Moreover, all patients who had active visible lesions when enrolled in the trial had complete healing of their lesions within weeks of treatment, a 100% response rate for this secondary end point.
Other content in this Stream
Annual Report 2018
2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.
Annual Report 2017